Effectivity and safety profile of tenapanor, a sodium-hydrogen exchanger isoform 3 inhibitor, as an innovative treatment for hyperphosphatemia in chronic kidney disease: A systematic review of clinical studies William Suciangto; Haerani Rasyid; Anastasya Angelica Vicente; Winny Suciangto;

Evaluation of clinical events and costs associated with the addition of dapagliflozin to chronic kidney disease treatment: Cost offset analysis Juan Francisco Navarro-González; Alberto Ortiz; Ana Cebrián Cuenca; Lluís Segú; Belén Pimentel; Unai Aranda; Blanca Lopez-Chicheri; Margarita Capel; Elisenda Pomares Mallol; Christian Caudron; Juan José García Sánchez; Roberto Alcázar Arroyo;